Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering CorpfiledCriticalSchering Corp
Priority to ARP000106728ApriorityCriticalpatent/AR027001A1/en
Publication of AR027001A1publicationCriticalpatent/AR027001A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describe el uso de desloratadina para la preparacion de un medicamento y o la prevencion de una condicion inflamatoria y alérgica de la piel o de lasvías aéreas superiores e inferiores en un paciente pediátrico y una composicíon farmacéutica efect iva para tal tratamiento y/o prevencion que comprende unacantidad efectiva de desloratadina y un vehículo farmacéuticamente aceptable.The use of desloratadine for the preparation of a medicament and the prevention of an inflammatory and allergic condition of the skin or upper and lower airways in a pediatric patient and an effective pharmaceutical composition for such treatment and / or prevention comprising an effective amount of desloratadine and a pharmaceutically acceptable carrier.
ARP000106728A2000-12-182000-12-18
TREATMENT OF ALLERGIC AND INFLAMMATORY CONDITIONS
AR027001A1
(en)
PHARMACEUTICAL COMPOSITION FOR A SUBJECT WHO NEEDS AN ELEVATION OF THE CONTENT OF NAD INTRACELLULAR, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE TO INCREASE THE PROTECTIVE CELLULAR RESPONSES TO GENOTOXIC STRESS IN THE SKIN
LACTAMA COMPOUND (N) - ((S) -2-HIDROXI-3-METHYLBUTIRILE) -1- (L-ALANINIL) - (S) -1-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO -2H-3-BENZAZEPIN-2-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE FOR THE INHIBITION OF THE B-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS THAT USES IT AND ITS USE FOR THE FABR
USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
Pharmaceutical composition containing loteprednol and antihistamines, a medicament containing these agents, a process for the preparation of the medicament and use of a combination of these agents
Cyclopentene derivatives, a pharmaceutical composition containing them and their use as a medicament for the treatment of motilin receptor-related disorders in humans
A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS
The use of saredutan and its pharmaceutically acceptable salts for the preparation of medicinal products useful in the treatment or prevention of all mental disorders, adaptation disorders and various anxiety-depression disorders.